Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

被引：0

作者：

Casneuf, Tineke ^{[1
]}

Lysaght, Andrew ^{[2
]}

LeFave, Clare ^{[3
]}

Bald, Jaime ^{[4
]}

Weiss, Brendan ^{[5
,6
]}

van de Donk, Niels W. C. J. ^{[7
]}

Lokhorst, Henk M. ^{[7
]}

Ahmadi, Tahamtan ^{[4
]}

Sasser, A. Kate ^{[4
]}

机构：

[1] Janssen Res & Dev, Beerse, Belgium

[2] Immuneering Corp, Cambridge, MA USA

[3] LabConnect LLC, Seattle, WA USA

[4] Janssen Res & Dev LLC, Spring House, PA USA

[5] Univ Penn, Dept Med, Div Hematol & Oncol, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[6] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[7] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU
McKeage K.
Lyseng-Williamson K.A.
Drugs & Therapy Perspectives, 2016, 32 (11) : 463 - 469
[2] Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M.
Plesner, T.
Laubach, J. P.
Nahi, H.
Gimsing, P.
Hansson, M.
Minnema, M. C.
Lassen, U.
Krejcik, J.
Palumbo, A.
van de Donk, N. W. C. J.
Ahmadi, T.
Khan, I.
Uhlar, C. M.
Wang, J.
Sasser, A. K.
Losic, N.
Lisby, S.
Basse, L.
Brun, N.
Richardson, P. G.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (13): : 1207 - 1219
[3] Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion
Verkleij, Christie P. M.
Frerichs, Kristine A.
Duetz, Carolien
Zweegman, Sonja
Homan-Weert, Paola M.
Minnema, Monique C.
Broyl, Annemiek
Levin, Mark-David
Bos, Gerard M. J.
Kersten, Marie Jose
Klein, Saskia K.
Shikhagaie, Medya M.
Krevvata, Maria
Casneuf, Tineke
Abraham, Yann
Verona, Raluca I.
Smets, Tina
Vanhoof, Greet
Cortes-Selva, Diana
van Steenbergen, Laure
Vieyra, Diego
Sonneveld, Pieter
Mutis, Tuna
van de Donk, Niels W. C. J.
BLOOD, 2021, 138
[4] Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma
Huang, Shang-Xiao
Luo, Peng-Hui
Wang, Han-Lei
Mo, Dun-Chang
Huang, Jian-Feng
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2667 - 2668
[5] Use of Daratumumab in Patients With Previously Treated Multiple Myeloma
Patel, Ashwin P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14)
[6] Daratumumab in multiple myeloma
Nooka, Ajay K.
Kaufman, Jonathan L.
Hofmeister, Craig C.
Joseph, Nisha S.
Heffner, Thomas L.
Gupta, Vikas A.
Sullivan, Harold C.
Neish, Andrew S.
Dhodapkar, Madhav, V
Lonial, Sagar
CANCER, 2019, 125 (14) : 2364 - 2382
[7] Daratumumab in multiple myeloma
Rajkumar, S. Vincent
LANCET, 2016, 387 (10027): : 1490 - 1492
[8] A new monoclonal antibody, Daratumumab monotherapy in the treatment of refractory or relapsed multiple myeloma
Richez, Valentine
Legros, Laurence
Leleu, Xavier
HEMATOLOGIE, 2015, 21 (05): : 260 - 261
[9] Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma
Yoon, Sung-Soo
Byun, Ja Min
Park, Hyunkyung
Lee, Ji Yun
Koh, Youngil
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E155 - E156
[10] Daratumumab for multiple myeloma
Croizier, Carolyne
Bailly, Sebastien
BULLETIN DU CANCER, 2018, 105 (11) : 985 - 991

← 1 2 3 4 5 →